LLY0 Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Eli Lilly and Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$19.20 |
52 Week High | US$25.20 |
52 Week Low | US$18.30 |
Beta | 0.37 |
1 Month Change | -0.52% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -1.50% |
Recent News & Updates
Recent updates
Shareholder Returns
LLY0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 4.3% | -2.2% | -1.4% |
1Y | n/a | -27.0% | 2.2% |
Return vs Industry: Insufficient data to determine how LLY0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LLY0 performed against the German Market.
Price Volatility
LLY0 volatility | |
---|---|
LLY0 Average Weekly Movement | 10.2% |
Pharmaceuticals Industry Average Movement | 6.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LLY0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LLY0's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
LLY0 fundamental statistics | |
---|---|
Market cap | €659.21b |
Earnings (TTM) | €5.75b |
Revenue (TTM) | €33.68b |
114.6x
P/E Ratio19.6x
P/S RatioIs LLY0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LLY0 income statement (TTM) | |
---|---|
Revenue | US$35.93b |
Cost of Revenue | US$7.13b |
Gross Profit | US$28.80b |
Other Expenses | US$22.66b |
Earnings | US$6.14b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
Earnings per share (EPS) | 6.82 |
Gross Margin | 80.16% |
Net Profit Margin | 17.08% |
Debt/Equity Ratio | 243.6% |
How did LLY0 perform over the long term?
See historical performance and comparison